A61K 31/407
Condensed with other heterocyclic ring systems
Official title: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
A61K31/407 (Condensed with other heterocyclic ring systems) appears on 1,647 US grants and 2,965 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,647
- Published applications
- 2,965
- Assignees
- 1,239
- Inventors
- 5,651
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 2 | 0 |
| 1995 | 4 | 0 |
| 1996 | 1 | 0 |
| 1997 | 14 | 0 |
| 1998 | 27 | 0 |
| 1999 | 30 | 0 |
| 2000 | 28 | 0 |
| 2001 | 20 | 11 |
| 2002 | 32 | 48 |
| 2003 | 32 | 93 |
| 2004 | 37 | 95 |
| 2005 | 20 | 84 |
| 2006 | 65 | 84 |
| 2007 | 24 | 59 |
| 2008 | 28 | 71 |
| 2009 | 25 | 94 |
| 2010 | 26 | 68 |
| 2011 | 29 | 76 |
| 2012 | 30 | 78 |
| 2013 | 49 | 140 |
| 2014 | 62 | 124 |
| 2015 | 85 | 156 |
| 2016 | 94 | 169 |
| 2017 | 104 | 164 |
| 2018 | 125 | 171 |
| 2019 | 109 | 160 |
| 2020 | 104 | 167 |
| 2021 | 100 | 176 |
| 2022 | 89 | 158 |
| 2023 | 55 | 145 |
| 2024 | 77 | 142 |
| 2025 | 82 | 136 |
| 2026 | 37 | 96 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Combinatory treatment29 Sep 2026US 12,746,216 B2Arivin Therapeutics Oy
- TEAD inhibitors29 Sep 2026US 12,747,207 B2Orion Corporation
- Pharmaceutical compounds and methods of making and using the same29 Sep 2026US 12,747,208 B2Athos Therapeutics, Inc.
- Treatment of low-grade intermediate-risk non-muscle-invasive bladder cancer with a thermally gelling pharmaceutical composition containing mitomycin22 Sep 2026US 12,740,940 B2Urogen Pharma Ltd.
- Compounds for the treatment of bacterial infections and potentiation of antibiotics8 Sep 2026US 12,728,105 B2Georgia State University Research Foundation, Inc.
- Guanidinylated Amphiphilic Tobramycin Derivates and B-Lactam/B-Lactamase Inhibitor Combinations for Treatment of Pseudomonas Aeruginosa Infections8 Oct 2026US 2026/0306524 A1
- Combination therapy for bacterial infections comprising zinc-chelator, beta-lactam antibiotic and serine beta-lactamase inhibitor8 Oct 2026US 2026/0306526 A1Adjutec Pharma AS
- Hexahydro[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine deuterated derivative, pharmaceutical composition thereof, preparation method therefor, and anti-influenza use thereof8 Oct 2026US 2026/0308174 A1Changsha Jingyi Pharmaceutical Technology Co., Ltd
- Pharmaceutical combinations and compositions thereof comprising antibacterial agents1 Oct 2026US 2026/0294871 A1
- Administration of low impurity/buffer free ketorolac phenylephrine compositions for therapeutic applications1 Oct 2026US 2026/0294872 A1
Most cited
By later US patents
- Therapeutic inhibitor of vascular smooth muscle cells562US 5,733,925 ANeoRx Corporation · 1998
- Therapeutic inhibitor of vascular smooth muscle cells438US 5,981,568 ANeoRx Corporation · 1999
- Therapeutic inhibitor of vascular smooth muscle cells308US 6,074,659 ANoeRx Corporation · 2000
- Therapeutic inhibitor of vascular smooth muscle cells280US 5,811,447 ANeoRx Corporation · 1998
- Therapeutic inhibitor of vascular smooth muscle cells245US 6,171,609 B2NeoRx Corporation · 2001